---
layout: default
title: Ganirelix
parent: 僅模型預測 (L5)
nav_order: 176
evidence_level: L5
indication_count: 10
---

# Ganirelix
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Ganirelix: Original Indication Not Documented → Predicted Association with Hypertrichosis (Low Confidence)

> **Note:** This Evidence Pack (`TW-DB06785-multi`) contains 10 TxGNN-predicted indications for ganirelix. All 10 are scored **L5 / Stage S0 / Recommendation: Hold**, and none have supporting clinical trials. This report focuses on the top-ranked prediction (hypertrichosis) but the conclusion applies to the full candidate set.

## One-Sentence Summary

The original approved indication for ganirelix is not documented in this Evidence Pack, and its mechanism of action is flagged as a data gap.
The TxGNN model's top prediction is **Hypertrichosis (disease)**, with a raw score of **99.98%**, but the model's own rationale states there is **no known mechanistic link** between GnRH antagonism and hair growth disorders — this is most likely an artifact of embedding-space clustering rather than a genuine pharmacological signal.
There are **0 clinical trials** and **0 publications** supporting this specific drug–disease pair.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not documented in this Evidence Pack (data gap) |
| Predicted New Indication | Hypertrichosis (disease) |
| TxGNN Prediction Score | 99.98% (rank #461 among all predictions) |
| Evidence Level | L5 (model prediction only, no clinical/literature evidence) |
| Germany Market Status | ✗ Not marketed (未上市) |
| Number of Authorizations | 0 |
| Recommended Decision | **Hold** |

---

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data for ganirelix is not available in this Evidence Pack, and no original indication is recorded. Without this baseline information, it is not possible to construct a pharmacologically grounded rationale connecting ganirelix to hypertrichosis.

More importantly, the Evidence Pack's own generated rationale for this pairing explicitly states:

> "多毛症與 GnRH 拮抗劑之生理機轉無已知關聯，可能為 TxGNN embedding 空間中因性腺軸相關疾病聚類產生的偽關聯。無機轉假說支持，無臨床證據。"
> ("There is no known physiological link between hypertrichosis and GnRH antagonists; this may be a spurious association arising from clustering of gonadal-axis-related diseases in the TxGNN embedding space. No mechanistic hypothesis is supported, and no clinical evidence exists.")

The same pattern holds across the remaining 9 predicted indications in this Evidence Pack — congenital hypertrichosis syndromes, periodontal/odontogenic malformation, Dandy-Walker malformation, hair shaft abnormalities, precocious puberty variants, persistent fetal circulation, aromatase excess syndrome, and trichomegaly. All are flagged with weak or absent mechanistic plausibility, and none carry direct clinical or literature support for ganirelix specifically. This is a case where the high TxGNN score does **not** correspond to biological or clinical plausibility.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

*(Note: rank #3 in this candidate set — "malformation syndrome with odontal/periodontal component" — has 20 associated PubMed articles, but all concern general periodontal disease pathophysiology and treatment; none reference ganirelix or GnRH antagonists. This reflects the volume of periodontal disease research generally, not evidence for this drug–disease pair, and is excluded from the top-ranked analysis above.)*

---

## Germany Market Information

Ganirelix is currently **not marketed** and has **0 authorizations** on record in this dataset. No license table is available.

---

## Safety Considerations

Please refer to the package insert for safety information.

*(Key warnings, contraindications, and drug interaction data are all marked as data gaps in this Evidence Pack. Notably, TFDA label/warning data (DG001) is flagged as a **Blocking** gap, meaning this candidate cannot proceed to Stage 1 safety review until resolved.)*

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
This candidate has no clinical trial or literature evidence supporting the drug–disease pair, no documented original indication, no MOA data, and is not currently marketed. The model's own mechanistic rationale explicitly identifies the top prediction as a likely embedding-space artifact rather than a genuine signal. All 10 predicted indications in this Evidence Pack score L5/S0/Hold, indicating a data quality and evidentiary gap rather than a repurposing opportunity ready for evaluation.

**To proceed, the following is needed:**
- TFDA label (仿單) warnings and contraindications — **Blocking gap (DG001)**, required before Stage 1 safety review
- Mechanism of action (MOA) data from DrugBank — **High-priority gap (DG002)**
- Documentation of ganirelix's original approved indication(s)
- Independent mechanistic hypothesis and/or preclinical evidence specifically linking GnRH antagonism to any of the predicted indications, before further clinical/literature evidence search is warranted
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

